Heparin-induced Thrombocytopenia Market Regional Analysis:
North American Market Insights
North America industry is likely to account for largest revenue share of 33% by 2035. This growth is assessed to be supported by an increased use of heparin in North America for the treatment of different disorders. Heparin is usually used for hemodialysis and the growing number of patients who are currently receiving dialysis will contribute to regional market development.
For instance, in February 2022, around 570,000 Americans received dialysis, which indicates a notable heparin usage and its adverse drug reaction, Heparin-induced thrombocytopenia. Apart from this, regional market growth in the forecast period will be stimulated by recent product introductions on the market. For example, Gland Pharma Ltd., together with its associates MAIA Pharmaceuticals Inc. and Athenex Pharmaceutical Division, launched a ready-to-use formulation of Bivalirudin in the United States in June 2020. This was the first on-frozen ready-to-use bivalirudin 505b (2) NDA authorized by the U.S.
European Market Insights
By 2035, Europe Region in heparin-induced thrombocytopenia market is anticipated to account for around 27% revenue share. Continuous research and development in the field are leading to the introduction of novel therapies with enhanced efficacy and reduced side effects.
This innovation is foreseen to attract new players and investments further propelling the market expansion in the region. Furthermore, government initiatives and favorable reimbursement policies for effective HIT treatments can incentivize the growth of the heparin-induced thrombocytopenia market and accessibility.
